Colorectal cancer (metastatic) - cetuximab (terminated appraisal) (TA150) (replaced by TA242)
Fast, easy summary view of NICE guidance on 'colorectal cancer'
Cetuximab for the treatment of metastatic colorectal cancer following failure of oxaliplatin-containing chemotherapy
This guidance has been replaced by TA242 Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: colorectal cancer
- None found
This page was last updated: 25 January 2012
Implementation tools and resources
- None available
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.